Patient adherence and the choice of antihypertensive drugs: Focus on lercanidipine

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1159-1166

  Pruijm, Menno T ^a   Maillard, Marc P ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Calcium antagonists; Compliance; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LERCANIDIPINE; RAMIPRIL;

ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FLUSHING; HEART PALPITATION; HUMAN; HYPERTENSION; LIPOPHILICITY; MONOTHERAPY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RENAL PROTECTION; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PROTEINURIA; TREATMENT OUTCOME;

EID: 60249101294     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Acanfora D, Gheorghiade M, Trojano L, et al. 2004. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther, 11:423-32.
2. Agrawal R, Marx A, Haller H. 2006. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens, 24:185-92.
3. Ambrosioni E, Leonetti G, Pessina A, Rappelli A, Trimarco B, et al. 2000. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens, 18:1691-9.
4. Angelico P, Guarnieri N, Leonardi A, et al. 1999. Vascular-selective effect of leranidipine and other 1,4 dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol, 51:709-14.
5. Arima S, Ito S, Omata K, et al. 1996. Role of actions of calcium antagonists on efferent arterioles with special references to glomerular hypertension. Am J Nephrol, 23:229-44.
6. Bang LM, Chapman TM, Goa KL. 2003. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs, 63:2449-72.
7. Barrios V, Escobar C, de la Figuera M, et al. 2008. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study. Cardiovasc Ther, 26:2-9.
8. Barrios V, Navarro A, Esteras A, et al. 2002. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press, 11:95-100.
9. Basile J. 2004. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens, 6:621-9.
10. Bloom BS. 1998. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther, 20:671-81.
11. Borghi C. 2005. Lercanidipine in hypertension. Vasc Health Risk Manag, 1:173-82.
12. Borghi C, Prandin MG, Dormi A, Ambrosioni E: Study group of the regional Unit of the Italian Society of Hypertension. 2003. Improved Tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl, 1:14-21.
13. Burnier M, Gasser UE. 2007. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother, 8:2215-23.
14. Burnier M, Santschi V, Favrat B, Brunner HR. 2003. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens, 21:S37-42.
15. Burnier M, Hess B, Greminger P, Waeber B. 2005. Determinants of persistence in hypertensive patients treated with Irbesartan: results of a postmarketing survey. BMC Cardiovasc Disords, 5:13.
16. Fogari R, Mugellini A, Zoppi A, et al. 2003. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens, 16:1357-69.
17. Caro JJ, Speckman JL, Salas M, et al. 1999. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ, 160:41-6.
18. Cleophas TJ, van Ouwekerk BM, van der Meulen J, et al. 2001. Diabetics with hypertension not controlled with ACE-inhibitors: alternate therapies. Angiology, 52:469-75.
19. Collins OR, Peto R. 1994. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, (ed). Textbook of Hypertension. Oxford, England: Blackwell Scientific Publications. p. 1156-64.
20. Croog SH, Levine S, Testa MA, et al. 1986. The effects of antihypertensive therapy on the quality of life. N Engl J Med, 314:1657-64.
21. Dahlöf B, Severs PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet, 366:895-906.
22. DeGiorgio LA, Orlandini F, Malasoma P, Zappa A. 1999. Double blind, cross-over study of lercanidipine versus amlodipine in the treatment of mild to moderate essential hypertension. Curr Ther Res, 60:511-20.
23. Douglas JG, Agodoa L. 2003. ACE-inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl, 83:S74-6.
24. Grandi AM, Solbiati F, Laurita E, et al. 2008. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens, 21:231-7.
25. Gress TW, Nieto FJ, Shahar E, et al. 2000. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med, 13:905-12.
26. Guillen VG, Abellan J, Llisterri JL, et al. 2003. Efficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study group. Am J Hypertens, 16:115A.
27. Gupta AK, Dahlöf B, Dobson J, et al. 2008. Determinants of new-onset diabetes among 189,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care, 31:982-8.
28. Hair PI, Scott LJ, Perry CM. 2007. Fixed-dose combination lercanidipine/ enalapril. Drugs, 67:95-106.
29. Hajjar I, Kotchen TA. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA, 290:199-206.
30. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. 1998. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular models to rationalize its pharmacokinetic properties. Blood Press Suppl, 2:10-7.
31. Hollenberg NK. 2002. Observations on the safety of lercanidipine: adverse events from placebo-controlled trials. Am J Hypertens, 15:58A-59A.
32. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordination Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. 1997. Arch Intern Med, 157:2413-46.
33. Jones JK, Gorkin L, Lian JF, et al. 1995. Discontinuation of and changes in treatment after start of new courses of antihypertensiv drugs: a study of a United Kingdom population. BMJ, 311:293-5.
34. Kruse W, Weber E. 1990. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol, 38:561-5.
35. Loghman-Adham M. 2003. Medication Noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care, 9:155-71.
36. Mancia G, De Backer Guy, Dominiczak A, et al. 2007. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25:1105-87.
37. Mason JM, Dickinson HO, Nicolson DJ, et al. 2005. The diabetogenic potential of thiazide-diuretic and beta blocker combinations in patients with hypertension. J Hypertens, 23:1779-81.
38. Morb Mortal Wkly Rep (MMWR). 2005. Racial/ethnic disparities in prevalence, treatment, and control of hypertension - United States 1999-2002. MMWR, 54:7-9.
39. Morgan SG, Yan L. 2004. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol, 11:267-73.
40. Nedeltchev K, Arnold M, Baumgartner R, et al. 2005. Vascular risk factors in the Swiss population. J Neurol, 252:1210-6.
41. Nuesch R, Schroeder K, Dieterle T, et al. 2001. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br Med J, 323:142-6.
42. Pedrinelli R, Dell'Omo G, Nuti M, et al. 2003. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens, 21:1969-73.
43. Poncelet P, Ribstein J, Goullard L, et al. 2004. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol, 53:123-30.
44. Poluzzi E, Strahinja P, Vargiu A. et al. 2005. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol, 61:603-9.
45. Puig JG, Calvo C, Luurila O, et al. 2007. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens, 21:917-24.
46. Pullar T, Kumar S, Feely M. 1989. Compliance in clinical trials. Ann Rheum Dis, 48:871-5.
47. Robles NR, Ocon J, Gomez CF, et al. 2005. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail, 1:73-80.
48. Sabbatini M, Leonardi A, Testa R, et al. 2000. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension, 35:775-9.
49. Sasaki T, Maruyama H, Kase Y, et al. 2005. Antianginal effects of lercanidipine on the vasopressin or metacholine induced anginal models in rats. Biol Pharm Bull, 28:811-6.
50. Shulman N, Cutter G, Daugherty R, et al. 1982. Correlates of attendance and compliance in the hypertension detection and follow-up program. Control Clin Trials, 3:13-27.
51. Simons LA, Ortiz M, Calcino G. 2008. Persistence with antihypertensive medication: Australia-wide experience 2004-6. Med J Aust, 188:224-7.
52. Sironi G, Montagna E, Greto L, et al. 1996. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung, 46:256-61.
53. Takabatake T, Ohta H, Sasaki T, et al. 1993. Renal effects of manidipine hydrochloride: a new calcium antagonist in hypertensive patients. Eur J Clin Pharmacol, 19:851-6.
54. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). 2002. JAMA, 288:2981-97.
55. Urquhart J, Vrijens B. 2005. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hospital Pharm Sci, 11:103-6.
56. Verdecchia P, Reboldi G, Angeli F, et al. 2005. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension, 46:386-92.
57. Veronesi M, Cicero AF, Prandin MG, et al. 2007. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag, 3:999-1005.
58. Voyaki SM, Staessen JA, Thijs L, et al. 2001. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens, 19:511-9.
59. Vrijens B, Vincze G, Kristano P, et al. 2008. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ, 336:1114-7.
60. Waeber B, Burnier M, Brunner HR. 1999. Compliance with antihypertensive treatment. Clin Exp Hypertens, 21:973-85.
61. Weir MR, Moser M. 2000. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J, 139:174-83.
62. World Health Organization: Adherence to long-term therapies. Evidence for action. 2003. Geneva: World Health Organization. URL: http://www.who.int/chronic_conditions/adherencereport/en/index.html.